← All trials
NCT05828277
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 28, 2022
- Primary completion
- Aug 31, 2025
- Completion date
- Dec 31, 2025
- First posted
- Apr 25, 2023
- Last posted
- Sep 26, 2023
- Enrollment
- 0
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Turning Point TherapeuticsLead sponsor
- Bristol-Myers SquibbOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.